[go: up one dir, main page]

TNSN99097A1 - Composition pharmaceutique a enrobage enterique et methode de fabrication - Google Patents

Composition pharmaceutique a enrobage enterique et methode de fabrication

Info

Publication number
TNSN99097A1
TNSN99097A1 TNTNSN99097A TNSN99097A TNSN99097A1 TN SN99097 A1 TNSN99097 A1 TN SN99097A1 TN TNSN99097 A TNTNSN99097 A TN TNSN99097A TN SN99097 A TNSN99097 A TN SN99097A TN SN99097 A1 TNSN99097 A1 TN SN99097A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical composition
manufacturing
enteric coated
coated pharmaceutical
medicinal
Prior art date
Application number
TNTNSN99097A
Other languages
English (en)
Inventor
Ullah Ismat
J Wiley Gary
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22179393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN99097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TNSN99097A1 publication Critical patent/TNSN99097A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ON PROPOSE UNE COMPOSITION PHARMACEUTIQUE A FORTE TENEUR MEDICAMENTEUSE ET A ENROBAGE ENTERIQUE QUI INCLUT UN NOYAU CONSTITUE D'UN MEDICAMENT QUI EST SENSIBLE A UN ENVIRONNEMENT DE FAIBLE pH DE MOINS DE 3, TEL QUE LE DDL, LA DITE COMPOSITION SE PRESENTANT DE PREFERENCE SOUS FORME DE PETITES PERLES AYANT UN ENROBAGE ENTERIQUE FORME DE COPOLYMERE D'ACIDE METHACRYLIQUE, D'UN PLASTIFIANT ET UN ENROBAGE SUPPLEMENTAIRE COMPRENANT UN ANTI-ADHERENT. LES PETITES PERLES AINSI NOMMEES PRESENTENT UNE EXCELLENTE RESISTANCE A LA DESINTEGRATION DANS UN pH INFERIEUR A 3 MAIS D'EXCELLENTES PROPRIETES DE LIBERATION DE LA SUBSTANCE MEDICAMENTEUSE DANS UN pH SUPERIEUR A 4,5. ON REVELE EGALEMENT UNE METHODE NOVATRICE POUR FABRIQUER LA DITE COMPOSITION PHARMACEUTIQUE.
TNTNSN99097A 1998-05-22 1999-05-20 Composition pharmaceutique a enrobage enterique et methode de fabrication TNSN99097A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8359798A 1998-05-22 1998-05-22

Publications (1)

Publication Number Publication Date
TNSN99097A1 true TNSN99097A1 (fr) 2005-11-10

Family

ID=22179393

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99097A TNSN99097A1 (fr) 1998-05-22 1999-05-20 Composition pharmaceutique a enrobage enterique et methode de fabrication

Country Status (39)

Country Link
US (2) US6224910B1 (fr)
EP (1) EP1079809B1 (fr)
JP (2) JP3798625B2 (fr)
KR (1) KR100484299B1 (fr)
CN (1) CN1149075C (fr)
AP (1) AP1206A (fr)
AR (1) AR017747A1 (fr)
AT (2) ATE311859T1 (fr)
AU (1) AU750911B2 (fr)
BG (1) BG65398B1 (fr)
BR (1) BR9815861A (fr)
CA (1) CA2332922C (fr)
CO (1) CO5070679A1 (fr)
CY (1) CY1119543T1 (fr)
CZ (1) CZ300497B6 (fr)
DE (2) DE1079809T1 (fr)
DK (2) DK1079809T3 (fr)
DZ (1) DZ2797A1 (fr)
EE (1) EE04926B1 (fr)
ES (1) ES2165833T3 (fr)
GE (1) GEP20033014B (fr)
HU (1) HU226491B1 (fr)
ID (1) ID27031A (fr)
IL (1) IL139274A (fr)
LT (1) LT4843B (fr)
LV (1) LV12602B (fr)
MA (1) MA26636A1 (fr)
NO (2) NO322903B1 (fr)
NZ (1) NZ508194A (fr)
OA (1) OA11512A (fr)
PL (1) PL193294B1 (fr)
RO (1) RO121674B1 (fr)
RU (1) RU2197227C2 (fr)
SK (1) SK284890B6 (fr)
TN (1) TNSN99097A1 (fr)
TR (1) TR200003373T2 (fr)
UA (1) UA69413C2 (fr)
WO (1) WO1999061002A1 (fr)
ZA (1) ZA993090B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
ATE438305T1 (de) 1998-03-23 2009-08-15 Gen Mills Inc Verkapselung von komponenten in essbaren produkten
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
JP2004520275A (ja) * 2000-11-10 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー 加水分解的に不安定な組成物
WO2002081050A1 (fr) * 2001-04-04 2002-10-17 Ngk Insulators, Ltd. Dispositif de traitement des eaux de pluie dans des eaux d'egout mixtes et procede de lavage a contre-courant associe
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
NZ532097A (en) * 2001-09-28 2006-02-24 Mcneil Ppc Inc Dosage forms having an inner core and outer shell
JP2005519052A (ja) 2002-01-11 2005-06-30 アスファルマ リミテッド プラバスタチン医薬製剤及びその使用方法
EP1905431A1 (fr) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Formulations pharmaceutiques de pravastatine et leurs procédés d'utilisation
US8399414B2 (en) * 2002-01-21 2013-03-19 Nrl Pharma, Inc. Analgesics
AU2002244881A1 (en) * 2002-03-22 2003-10-08 Ranbaxy Laboratories Limited Controlled release drug delivery system of pravastatin
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1551356A2 (fr) * 2002-09-03 2005-07-13 Biovail Laboratories Incorporated Formulations pharmaceutiques de pravastatin et leurs modes d'utilisation
CA2497832A1 (fr) * 2002-09-03 2004-03-18 Biovail Laboratories International Srl Formulations pharmaceutiques et procedes de liberation modifiee de statines
WO2004087175A1 (fr) * 2003-04-04 2004-10-14 Pharmacia Corporation Tablettes comprimees orales de formulations multiparticulaires a liberation prolongee
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
WO2005055955A2 (fr) * 2003-12-09 2005-06-23 Pharmasset, Inc. PROCEDES DE DOSAGE DESTINES A UNE THERAPIE ANTIVIRALE A BASE DE ss-D-2',3'-DIDEOXY-2',3'-DIDEHYDRO-5-FLUOROCYTIDINE
PT1729797E (pt) * 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006055742A1 (fr) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
CA2588400A1 (fr) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Bille a enrobage enterique comprenant de l'ixabepilone et son procede de preparation
WO2006054175A2 (fr) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Formes posologiques stables de medicament labile en milieu acide
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP1913138B1 (fr) * 2005-07-29 2016-08-24 Abbott Laboratories GmbH Procédé de fabrication de poudre de pancréatine avec faible contenu viral
US11744803B2 (en) 2005-07-29 2023-09-05 Stichting Groningen Centre for Drug Rese PH-controlled pulsatile delivery system, methods for preparation and use thereof
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
EP1931316B2 (fr) 2005-08-15 2017-02-22 Abbott Laboratories GmbH Compositions pharmaceutiques a liberation controlee destinees a des medicaments acido-labiles
DE602006004471D1 (de) * 2005-08-15 2009-02-05 Solvay Pharm Gmbh Pankreatin-mikropellets geeignet für magensaftresistente überzüge
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007072060A2 (fr) * 2005-12-23 2007-06-28 Cipla Limited Composition pharmaceutique
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
HRP20140783T1 (hr) 2008-04-24 2014-09-12 Bristol-Myers Squibb Company Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
GB2484929A (en) 2010-10-25 2012-05-02 Maria Christiana Peter Geraedts An edible product including plant protein
RU2442572C1 (ru) * 2010-12-23 2012-02-20 Ольга Львовна Титова Энтеросолюбильная оболочка и композиция для ее получения
KR20120135063A (ko) * 2011-06-01 2012-12-12 닛토덴코 가부시키가이샤 입자 제제 및 그 제조 방법
US10117447B1 (en) * 2013-03-15 2018-11-06 The United States Of America, As Represented By The Secretary Of Agriculture Extrusion of high density hydroxypropylmethylcellulose edible flexible gels
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
CN104758180A (zh) * 2014-01-06 2015-07-08 山东诚创医药技术开发有限公司 一种复方制剂胶囊的二次填充方法
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
JP6955648B2 (ja) 2015-09-01 2021-10-27 ファースト ウェーブ バイオ インコーポレイテッド 異常炎症反応に関連する状態を処置するための方法および組成物
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
RU2670447C2 (ru) * 2016-11-17 2018-10-23 Общество с ограниченной ответственностью "Изварино Фарма" Пероральная твердая лекарственная форма с микофенольной кислотой или ее солью для использования в качестве иммунодепрессанта для лечения или предупреждения отторжения трансплантата органа или ткани и способ ее получения
US20180369296A1 (en) 2017-05-26 2018-12-27 Animal Microbiome Analytics, Inc. Products and Methods for Therapeutic Administration of Microorganisms to Non-Human Animals
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
CN111280449B (zh) * 2020-02-11 2022-11-11 浙江华康药业股份有限公司 一种肠内缓释糖醇添加剂及其制备方法和应用
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
WO1987001284A1 (fr) 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition du caractere infectieux et de l'effet cytopathique du htlv-iii/lav in vitro par la 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, ou 2',3'-dideoxyadenosine
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
WO1988002629A1 (fr) * 1986-10-16 1988-04-21 American Health Products Corporation Composition de didesoxyadenosine-2',3'
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
SE460946B (sv) * 1987-03-16 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av kinidinglukonat
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
PH30058A (en) * 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
CA2141582C (fr) 1992-08-05 2003-09-30 Angelo Mario Morella Composition pharmaceutique sous forme de pastilles
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
EP0689840A1 (fr) * 1994-06-28 1996-01-03 Spirig Ag Pharmazeutische Präparate Nouvelle composition pharmaceutique contenant de l'érythromycine base libre
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I

Also Published As

Publication number Publication date
PL344259A1 (en) 2001-10-22
ES2165833T3 (es) 2006-05-16
DE1079809T1 (de) 2002-08-22
DK1079809T3 (da) 2006-02-20
NO20062106L (no) 1999-11-23
TR200003373T2 (tr) 2001-03-21
IL139274A0 (en) 2001-11-25
RU2197227C2 (ru) 2003-01-27
BG105061A (bg) 2001-07-31
CY1119543T1 (el) 2018-04-04
UA69413C2 (uk) 2004-09-15
AR017747A1 (es) 2001-10-24
AP2000001988A0 (en) 2000-12-31
EE200000680A (et) 2002-10-15
CZ20004362A3 (en) 2001-05-16
HK1034461A1 (en) 2001-10-26
JP2006022115A (ja) 2006-01-26
KR20010043736A (ko) 2001-05-25
LT2000105A (lt) 2001-04-25
GEP20033014B (en) 2003-07-25
BR9815861A (pt) 2001-01-16
SK284890B6 (sk) 2006-02-02
KR100484299B1 (ko) 2005-04-20
NZ508194A (en) 2003-07-25
WO1999061002A1 (fr) 1999-12-02
CA2332922A1 (fr) 1999-12-02
MA26636A1 (fr) 2004-12-20
CZ300497B6 (cs) 2009-06-03
AU750911B2 (en) 2002-08-01
DE69832731D1 (de) 2006-01-12
DZ2797A1 (fr) 2003-12-01
HU226491B1 (en) 2009-03-02
CN1294509A (zh) 2001-05-09
SK16302000A3 (sk) 2001-08-06
DE69832731T2 (de) 2006-09-14
CN1149075C (zh) 2004-05-12
EP1079809B1 (fr) 2005-12-07
PL193294B1 (pl) 2007-01-31
NO20005879L (no) 2001-01-18
LV12602A (en) 2001-01-20
LV12602B (en) 2001-07-20
OA11512A (en) 2004-02-03
AT6311U1 (de) 2003-08-25
ATE311859T1 (de) 2005-12-15
NO20005879D0 (no) 2000-11-21
ZA993090B (en) 2000-11-06
IL139274A (en) 2004-12-15
EP1079809A1 (fr) 2001-03-07
JP2002516268A (ja) 2002-06-04
CO5070679A1 (es) 2001-08-28
DK200200229U3 (da) 2003-01-24
ES2165833T1 (es) 2002-04-01
NO322903B1 (no) 2006-12-18
RO121674B1 (ro) 2008-02-28
AU8685498A (en) 1999-12-13
LT4843B (lt) 2001-09-25
HUP0101714A3 (en) 2002-10-28
US20010005716A1 (en) 2001-06-28
HUP0101714A2 (hu) 2002-01-28
JP3798625B2 (ja) 2006-07-19
CA2332922C (fr) 2008-02-12
BG65398B1 (bg) 2008-06-30
AP1206A (en) 2003-09-18
EE04926B1 (et) 2007-12-17
US6224910B1 (en) 2001-05-01
EP1079809A4 (fr) 2001-11-07
ID27031A (id) 2001-02-22

Similar Documents

Publication Publication Date Title
TNSN99097A1 (fr) Composition pharmaceutique a enrobage enterique et methode de fabrication
US5292522A (en) Aqueous film coating agent for solid medicaments
Alem et al. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
EP0605174B1 (fr) Préparation pharmaceutique à libération retardée et continue
US5068110A (en) Stabilization of enteric coated dosage form
US5885615A (en) Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose
GEP20032912B (en) Enteric Coated Pharmaceutical Tablets and Method of Manufacturing
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
AU576891B2 (en) Biphasic release tablet with drug in polymercoat and drug in the core
SK792001A3 (en) Coating and excipient agent for oral or dermal dosage forms
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
FR2603458A1 (fr) Nouvelles compositions pour l'enrobage des additifs alimentaires destines aux ruminants et additifs alimentaires ainsi enrobes
WO1998009597A3 (fr) Boulettes tampons et comprime les renfermant pour former une suspension
EP0040439A2 (fr) Préparations granulaires à libération continue
KR880010758A (ko) 서방성 제제
WO2003041690A3 (fr) Impression ou distribution d'une suspension, de type impression tridimensionnelle de formes galeniques
KR930003905A (ko) 약학적 결합 제제
KR870000069A (ko) 안정한 고체 제형의 제조 방법
BR0014966A (pt) Composição de revestimento de pronta liberação, endurecìvel e comestìvel
Rose et al. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643
MXPA05008033A (es) Composiciones de milnacipran en forma de multiparticulas para administracion oral.
Jiao et al. Preparation and characterization of heparin-loaded polymeric microparticles
EP2260836A3 (fr) Comprimé a libération rapide avec un noyau comprenant le principe actif enrobé dans une barrière masquant le gout
Nidhi et al. Development of enteric-coated microspheres of embelin for their beneficial pharmacological potential in ulcerative colitis